Tatsuaki Watanabe

Tatsuaki Watanabe

Auto-generated profile, based on publicly available information

Tatsuaki Watanabe

Department of Thoracic Surgery, Tohoku University Hospital, Sendai, Miyagi, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
TWTatsuaki Watanabe
Tatsuaki Watanabe
TMTereza Martinu
Tereza Martinu
ACAndrzej Chruscinski
Andrzej Chruscinski
KBKristen Boonstra
Kristen Boonstra
BJBetty Joe
Betty Joe
SJStephen Juvet
Stephen Juvet
Chronic lung allograft dysfunction (CLAD) limits long-term survival after lung transplant (LT). Ischemia–reperfusion injury (IRI) promotes chronic rejection (CR) and CLAD, but the underlying mechanisms are not well understood. To examine mechanisms linking IRI to CR, a mouse orthotopic LT model using a minor alloantigen strain mismatch (C57BL/10 [B10, H-2b] → C57BL/6 [B6, H-2b]) and isograft controls (B6→B6) was used with antecedent minimal or prolonged graft storage. The latter resulted in IRI with subsequent airway and parenchymal fibrosis in prolonged storage allografts but not isografts. This pattern of CR after IRI was associated with the formation of B cell–rich tertiary lymphoid organs within the grafts and circulating autoantibodies. These processes were attenuated by B cell depletion, despite preservation of allograft T cell content. Our observations suggest that IRI may promote B cell recruitment that drives CR after LT. These observations have implications for the mechanisms leading to CLAD after LT.

10 September 2018 in Surgery Today
Verified
Journal Article
Closed access
PDF file
TWTatsuaki Watanabe
Tatsuaki Watanabe
HSHideo Shimomura
Hideo Shimomura
TMTatsushi Mutoh
Tatsushi Mutoh
RSRyoko Saito
Ryoko Saito
RGRyoi Goto
Ryoi Goto
YOYoshinori Okada
Yoshinori Okada

29 November 2021 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
THTakashi Hirama
Takashi Hirama
MAMiki Akiba
Miki Akiba
TWTatsuaki Watanabe
Tatsuaki Watanabe
YWYui Watanabe
Yui Watanabe
HNHirotsugu Notsuda
Hirotsugu Notsuda
YOYoshinori Okada
Yoshinori Okada
Background: As lung transplantation (LTX) is a valuable treatment procedure for end-stage pulmonary disease, delayed referral to a transplant center should be avoided. We aimed to conduct a single-center analysis of the survival time after listing for LTX and waitlist mortality in each disease category in a Japanese population. Methods: We included patients listed for LTX at Tohoku University Hospital from January 2007 to December 2020 who were followed up until March 2021. Pulmonary disease was categorized into the Obstructive, Vascular, Suppurative, Fibrosis, and Allogeneic groups. Risk factors for waitlist mortality were assessed using a Cox proportional hazards model. The Kaplan–Meier method was used to model time to death. Results: We included 269 LTX candidates. Of those, 100, 72, and 97 patients were transplanted, waiting, and dead, respectively. The median time to LTX and time to death were 796 days (interquartile range [IQR] 579–1056) and 323 days (IQR 129–528), respectively. The Fibrosis group showed the highest mortality (50.9%; p < .001), followed by the Allogeneic (35.0%), Suppurative (33.3%), Vascular (32.1%), and Obstructive (13.1%) groups. The Fibrosis group showed a remarkable risk for waitlist mortality (hazard ratio 3.32, 95% CI 2.11–4.85). Conclusions: In Japan, the waiting time is extremely long and candidates with Fibrosis have high mortality. There is a need to document outcomes based on the underlying disease for listed LTX candidates to help determine the optimal timing for listing patients based on the estimated local waiting time.

5 April 2024 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
THTakashi Hirama
Takashi Hirama
YSYuki Shundo
Yuki Shundo
TWToshikazu Watanabe
Toshikazu Watanabe
AOAkihiro Ohsumi
Akihiro Ohsumi
TWTatsuaki Watanabe
Tatsuaki Watanabe
YOYoshinori Okada
Yoshinori Okada
Letermovir, initially approved for cytomegalovirus (CMV) prophylaxis in hematopoietic stem-cell transplantation, has gained attention for off-label use in lung-transplant (LTx) recipients. Given the high susceptibility of LTx recipients to CMV infection, this study explores the effectiveness and safety of letermovir prophylaxis. A retrospective analysis of using letermovir for LTx recipients at Tohoku University Hospital (January 2000 to November 2023) was conducted. Case summaries from other Japanese transplant centers and a literature review were included. Six cases at Tohoku University Hospital and one at Kyoto University Hospital were identified. Prophylactic letermovir use showed positive outcomes in managing myelosuppression and preventing CMV replication. The literature review supported the safety of letermovir in high-risk LTx recipients. Despite limited reports, our findings suggest letermovir’s potential as prophylaxis for LTx recipients intolerant to valganciclovir. Safety, especially in managing myelosuppression, positions letermovir as a promising option. However, careful consideration is important in judiciously integrating letermovir into the treatment protocol.

2 February 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
TWTatsuaki Watanabe
Tatsuaki Watanabe
MKMitsuaki Kawashima
Mitsuaki Kawashima
MKMikihiro Kohno
Mikihiro Kohno
JYJonathan Yeung
Jonathan Yeung
James DownarJames Downar
James Downar
MCMarcelo Cypel
Marcelo Cypel
Over 2.5% of deaths in Canada occur as a result from Medical Assisting in Dying (MAID), and a subset of these deaths result in organ donation. However, detailed outcomes of lung transplant recipients using these donors is lacking. This is a retrospective single center cohort study comparing lung transplantation outcomes after donation using MAID donors compared to neurologically determined death and controlled donation after circulatory death (NDD/cDCD) donors from February 2018 to July 2021. Thirty-three patients received lungs from MAID donors, and 560 patients received lungs from NDD/cDCD donors. The donor diagnoses leading to MAID provision were: degenerative neurological diseases (n=33), and end stage organ failure (n=5). MAID donors were significantly older than NDD/cDCD donors [56 (IQR 49-64) years vs. 48 (32-59); P = .0009]. Median ventilation period and 30 days mortality were not significantly different between MAID and NDD/cDCD lungs recipients (ventilation: 1 day (1-3) vs 2 days (1-3); p=.37, deaths 0% (0/33) vs. 2% (11/560), p=.99 respectively). Intermediate-term outcomes were also similar. In summary, lung transplantation using donors after MAID, recipient outcomes are excellent. Therefore, where this practice is permitted, donation after MAID should be strongly considered for lung transplantation as a way to respect donor wishes while substantially improving outcomes for recipients with end-stage lung disease.

2 August 2016 in Surgery Today
Verified
Journal Article
Closed access
PDF file
TWTatsuaki Watanabe
Tatsuaki Watanabe
YHYasushi Hoshikawa
Yasushi Hoshikawa
NINaoya Ishibashi
Naoya Ishibashi
HSHirotoshi Suzuki
Hirotoshi Suzuki
HNHirotsugu Notsuda
Hirotsugu Notsuda
YOYoshinori Okada
Yoshinori Okada